DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.

Moovcare® is a medical application that needs to be prescribed by your oncologist and helps you stay connected to your medical team. If your physician determines that you are eligible to be included into Moovcare® platform, you will start receiving a digital questionnaire once a week, which you can answer via your smartphone, laptop or tablet.

You will be required to self report your symptoms, Moovcare® algorithm will analyse your answers and if it detects an anomaly or complication, an immediate notification will be sent to your treating physician. Moovcare is a digital therapeutic that uses a simple questionnaire to detect relapse or complications during follow-up of lung cancer patients. It enables monitoring patient symptoms on a weekly basis and alerting medical teams to the first signs of an anomaly. It was founded in 2014 and is based in Jerusalem, Israel.

We are a multidisciplinary team of clinicians, technologists, and behavioral experts united to tackle some of the most significant challenges in healthcare.

Drawing on multi-year clinical studies conducted by leading oncologists in the US and France, we have developed the first digital platform for the early detection of diseases. These studies highlight the impact of patient-reported symptoms on survival and quality of life, forming the foundation of our innovative approach.

Moovcare® was proven in a clinical study to significantly improve lung cancer patients’ well being, as well as the communication with the medical team.